Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ADA | P00813 | 3/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20664871 | 0.83 | HIF1A (0.44) | HIF1AASAH1 | |
| SCHEMBL21311454 | 0.80 | HIF1A (0.36) | HIF1AADAASAH1FAAH | |
| SCHEMBL21311342 | 0.79 | MEN1 (0.53) | ADAASAH1CNR1CNR2 | |
| SCHEMBL7196866 | 0.77 | HIF1A (0.37) | HIF1AADAASAH1 | |
| SCHEMBL1106477 | 0.76 | HIF1A (0.45) | HIF1A | |
| SCHEMBL20970104 | 0.76 | RPS6KA5 (0.40) | ADAASAH1 | |
| SCHEMBL23760241 | 0.73 | HIF1A (0.43) | HIF1A | |
| SCHEMBL13749801 | 0.73 | LTA4H (0.49) | ASAH1CNR1CNR2 | |
| SCHEMBL21591572 | 0.73 | HIF1A (0.39) | HIF1AASAH1 | |
| SCHEMBL10163442 | 0.71 | LTA4H (0.50) | ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338132-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338132-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | AHR, HCLS1, ARNT | HIF1A 390/4885ADA 992/4885ASAH1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.